nsp14-ExoN Archives

The Trend Reduction In COVID-19 Daily Deaths.

30 April 2022

SARS-CoV-2 Was Waving A White Flag By June 2020. Since the onset of the Great Insanity we have been following the COVID-19 mortality rate and total deaths on a daily basis, as mortality rate is ultimately the best measure of infectivity, i.e. the damage to human health that a pathogen can cause. For an explanation […]

What Makes SARS-CoV-2 More Infectious.

12 February 2022

The Role Of The RBM:ACE2 Interface. A little over a year ago, we set out how increased infectiousness meant greater vulnerability, i.e. a new variant may be more infectious but it is also more susceptible to destruction by the innate immune response. The chances are that most people now know what a structural spike protein […]

How Each Of Us Causes Every Variant.

31 January 2022

The Four Nucleobases. Almost exactly twelve months ago, we explained how increased transmissibility also meant greater vulnerability, i.e. a new variant may be more infectious but it is also more susceptible to detection by the immune system. This was first evidenced by our study of SARS-CoV-2-SG614, also one year ago now. Despite there being virtually […]

Why The S Protein Is Not The Target You Are Looking For.

11 February 2021

The First Lesson Of Camouflage – Not Being Seen. The majority of vaccines and antivirals both in use and in development as SARS-CoV-2 countermeasures target the structural Spike protein. We have highlighted previously that as the S protein trimers contain the RBDs, the S protein houses the virion’s principal weapon and is therefore the obvious, […]

More Infectious Equals More Vulnerable.

28 January 2021

Infectiousness And Infectivity Are Not The Same. Infectiousness is how easily a pathogen can spread and infectivity is the level of disease severity it can cause. We explained this in more detail earlier this month in response to the UK government’s regular – and one would predicate deliberate – confusion of the two. S-VoC / […]

Antibody-Dependent Enhancement And This Rushed ‘Vaccine’.

19 January 2021

What is Antibody-Dependent Enhancement? As we have set out previously, it takes 10-15 years to develop a vaccine. This timescale is entirely understandable and justifiable when you consider that the vaccine has to be both effective and safe. Safe includes not causing unacceptable side effects, which include the vaccine or immune system’s response triggering autoimmunity, […]

Exoribonuclease – Your Starter For Ten Mr Prime Minister.

30 December 2020

Q1. How can a virus containing an exoribonuclease mutate in the way you are saying? Coronaviruses possess an exoribonuclease within nonstructural protein 14 (nsp14-ExoN). This functions as a proofreader during viral transcription and encoding, ensuring high fidelity replication. This minimises the potential for mutation, as shown by the fact that sarbecovirus/lineage B betacoronaviruses with their […]

PCR Testing Is Picking Up The Common Cold.

23 December 2020

Mutation = Phylogenetic Evolution. Not content with inventing the most recent ‘killer mutation of death’, there are now apparently even more new strains of the ‘killer virus of death’ (the one that continues to not kill people, especially those it infects). There is now even one supposedly from South Africa (“this is an illegal mutating, […]

Mutation Makes A Vaccine Useless.

20 December 2020

Epitopes And Paratopes. Apparently the killer virus of death (the one that continues to not kill people, especially those it infects) has now mutated into an even more killer strain. If that’s true – which it isn’t, read on to find out why – then wonderdrug vaccine BNT126b2 is nothing of the sort: it was […]

These Are Not The Drugs You Are Looking For.

20 November 2020

Don’t Use Remdesivir. Just one month after the US Food and Drug Administration approved remdesivir as an antiviral for the treatment of patients with COVID-19, the WHO yesterday recommended that it not be used, on the basis that it is ineffective and there is “no evidence” it reduces mortality. Last month, we analysed remdesivir’s use […]